Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative therapeutic efficacy and adverse effects of anti-COVID-19 drugs.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Inflammation, cardiovascular complications, Anti-COVID-19 Therapy, 【초록키워드】 coronavirus, stroke, drugs, Intervention, cardiovascular diseases, drug, Venous Thromboembolism, global pandemic, adverse effects, heart failure, myocardial injury, COVID-19 infection, myocarditis, Patient, death, Myocardial infarction, Arrhythmias, COVID-19 patient, adverse effect, cardiovascular complication, acute respiratory syndrome, higher risk, therapeutic efficacy, addition, cardiovascular comorbidity, 【제목키워드】 drug, cardiovascular, Adverse, Effect,
【저자키워드】 COVID-19, SARS-CoV-2, Inflammation, cardiovascular complications, Anti-COVID-19 Therapy, 【초록키워드】 coronavirus, stroke, drugs, Intervention, cardiovascular diseases, drug, Venous Thromboembolism, global pandemic, adverse effects, heart failure, myocardial injury, COVID-19 infection, myocarditis, Patient, death, Myocardial infarction, Arrhythmias, COVID-19 patient, adverse effect, cardiovascular complication, acute respiratory syndrome, higher risk, therapeutic efficacy, addition, cardiovascular comorbidity, 【제목키워드】 drug, cardiovascular, Adverse, Effect,